Publications by authors named "Juliet Williams"

Claim this Profile
D
Discovery of Selective and Orally Bioavailable Heterobifunctional Degraders of Cyclin-Dependent Kinase 2.
Philip N Collier, Xiaozhang Zheng, Melissa Ford, Matthew Weiss, Dapeng Chen, Juliet Williams

J Med Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors.
Yogesh K Chutake, Michele F Mayo, Nancy Dumont, Jessica Filiatrault, Susanne B Breitkopf, Juliet A Williams

Mol Cancer Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers.
Nicholas Kwiatkowski, Tong Liang, Zhe Sha, Philip N Collier, Annan Yang, Juliet Williams

Cell Chem Biol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Hui Qin Wang, Iain J Mulford, Fiona Sharp, Jinsheng Liang, Sema Kurtulus, Juliet A Williams

Cancer Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Chen Liu, Hengyu Lu, Hongyun Wang, Alice Loo, Xiamei Zhang, Juliet A Williams

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts.
Adam C Palmer, Deborah Plana, Hui Gao, Joshua M Korn, Guizhi Yang, Juliet A Williams

Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies.
Haihui Lu, Ryan D Molony, Dongshu Chen, Sunyoung Jang, Babette Wolf, Juliet A Williams

Mol Cancer Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Huai-Xiang Hao, Hongyun Wang, Chen Liu, Steven Kovats, Roberto Velazquez, Juliet Williams

Mol Cancer Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct Transcriptional Programming Drive Response to MAPK Inhibition in -Mutant Melanoma Patient-Derived Xenografts.
Tianshu Feng, Javad Golji, Ailing Li, Xiamei Zhang, David A Ruddy, Juliet A Williams

Mol Cancer Ther· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Leila Dardaei, Hui Qin Wang, Manrose Singh, Paul Fordjour, Katherine X Shaw, Juliet Williams

Nat Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field.
Juliet A Williams

J Clin Med· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting human clinical trial responses in mice.
Hui Gao, Juliet Anne Williams

Mol Cell Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilizing panels of patient derived xenografts to aid the development of antibody drug conjugates.
Scott David Collins, Carl Uli Bialucha, Juliet Anne Williams, Hui Gao

Mol Cell Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
Elsa Beyer Krall, Belinda Wang, Diana M Munoz, Nina Ilic, Srivatsan Raghavan, Juliet A Williams

Elife· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers.
Carl U Bialucha, Scott D Collins, Xiao Li, Parmita Saxena, Xiamei Zhang, Juliet Williams

Cancer Discov· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival.
Haizhen Wang, Brandon N Nicolay, Joel M Chick, Xueliang Gao, Yan Geng, Juliet A Williams

Nature· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human mutant neuroblastoma cell lines and xenograft models.
Hui Qin Wang, Ensar Halilovic, Xiaoyan Li, Jinsheng Liang, Yichen Cao, Juliet A Williams

Elife· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
Elsa B Krall, Belinda Wang, Diana M Munoz, Nina Ilic, Srivatsan Raghavan, Juliet A Williams

Elife· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
Hui Gao, Joshua M Korn, Stéphane Ferretti, John E Monahan, Youzhen Wang, Juliet A Williams

Nat Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened.
Stefan Peukert, Feng He, Miao Dai, Rui Zhang, Yingchuan Sun, Juliet Williams

ChemMedChem· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.
Alexandra E Gould, Ruth Adams, Sharmila Adhikari, Kathleen Aertgeerts, Roushan Afroze, Juliet Williams

J Med Chem· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Silvia Buonamici, Juliet Williams, Michael Morrissey, Anlai Wang, Ribo Guo

Sci Transl Med· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.
Christopher Blackburn, Matthew O Duffey, Alexandra E Gould, Bheemashankar Kulkarni, Jane X Liu, Juliet Williams

Bioorg Med Chem Lett· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.
Shifeng Pan, Xu Wu, Jiqing Jiang, Wenqi Gao, Yongqin Wan, Juliet Williams

ACS Med Chem Lett· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity.
Karen Miller-Moslin, Stefan Peukert, Rishi K Jain, Michael A McEwan, Rajesh Karki, Juliet Williams

J Med Chem· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis